A multicenter phase II trial of domestic product of zoledronic acid in the treatment of malignant hypercalcemia

被引：1
作者：
Lijun Di
机构：
来源：
Chinese-German Journal of Clinical Oncology | 2007年 / 04期
关键词：
malignant hypercalcemia; zoledronic acid; phase II clinical trial;
D O I：
暂无
中图分类号：
R730.5 [肿瘤治疗学];
学科分类号：
100214 ;
摘要：
Objective:To evaluate the effect and safety of clinical use of zoledronic acid in the treatment of malignant hypercalcemia.Methods:A multi-center,open phase II clinical trial was conducted in 15 cases with malignant hypercalcemia who received zoledronic acid intravenously for 15 min.The level of blood calcium and side effects were recorded regularly within 28 days after injection.Results:One case was dropped out due to bad compliance.The complete response rate(the corrected serum calcium was reduced to normal level)was 100.00%(14/14).The medium time of complete response rate was 5.07 days.The medium maintain time was 22.30 days.Slight,or moderate fever was observed.Conclusion:Zoledronic acid can effectively reduce the malignant hypercalcemia.The use of zoledronic acid appears to be safety and convenient.
引用
收藏
页码：393 / 395
页数：3
相关论文
共 3 条
  • [1] Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma[J] . Lee S.Rosen,DavidGordon,MaryKaminski,AnthonyHowell,AndrewBelch,JohnMackey,JustusApffelstaedt,Mohamad A.Hussein,Robert E.Coleman,Dirk J.Reitsma,Bee‐LianChen,John J.Seaman.Cancer . 2003 (8)
  • [2] Zoledronic acid: A new parenteral bisphosphonate[J] . Edward C. Li,Lisa E. Davis.Clinical Therapeutics . 2003 (11)
  • [3] Pamidronate （Aredia） and zoledronate （Zometa） induced avascular necrosis of the jaws: a growing epidemic[J] . Robert E Marx.Journal of Oral and Maxillofacial Surgery . 2003 (9)
1